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Summary
There is an urgent need for the development of new therapeutic
strategies for Alzheimer’s disease (AD). The dual-specificity
tyrosine phosphorylation-regulated kinase-1A (Dyrk1a) is a pro-
tein kinase that phosphorylates the amyloid precursor protein
(APP) and tau and thus represents a link between two key
proteins involved in AD pathogenesis. Furthermore, Dyrk1a is
upregulated in postmortem human brains, and high levels of
Dyrk1a are associated with mental retardation. Here, we sought
to determine the effects of Dyrk1 inhibition on AD-like pathology
developed by 3xTg-AD mice, a widely used animal model of AD.
We dosed 10-month-old 3xTg-AD and nontransgenic (NonTg)
mice with a Dyrk1 inhibitor (Dyrk1-inh) or vehicle for
eight weeks. During the last three weeks of treatment, we
tested the mice in a battery of behavioral tests. The brains were
then analyzed for the pathological markers of AD. We found that
chronic Dyrk1 inhibition reversed cognitive deficits in 3xTg-AD
mice. These effects were associated with a reduction in amyloid-b
(Ab) and tau pathology. Mechanistically, Dyrk1 inhibition reduced
APP and insoluble tau phosphorylation. The reduction in APP
phosphorylation increased its turnover and decreased Ab levels.
These results suggest that targeting Dyrk1 could represent a new
viable therapeutic approach for AD.
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Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative
disorder, which affects about 5.5 million people in the United States
and 40 million worldwide (Alzheimer’s, 2015). There is an urgent need
for developing new therapeutic approaches as the current FDA approved
medications have no effects on the progression of the disease. If the
current status quo is not altered by the introduction of new therapeutic
strategies able to slow down or halt the progression of the disease, it is
estimated that by 2050, 12 million people in the United States will have
AD (Alzheimer’s, 2015).
Accumulation of amyloid-b (Ab) and hyperphosphorylated tau is a
critical event in the pathogenesis of AD (Querfurth & LaFerla, 2010). Tau
is a microtubule-binding protein; one of the most well-known functions
of tau is to bind to and stabilize microtubules (Querfurth & LaFerla,
2010). This property is regulated by phosphorylation events, with
phosphorylated tau having less affinity for microtubules. Pathological
tau is hyperphosphorylated and produces soluble and insoluble inclu-
sions, which form neurofibrillary tangles (NFTs) characteristic of AD and
other tauopathies (Medina et al., 2016). To this end, inhibiting the
activity of known tau kinases could be a valid approach to reduce the
formation of NFTs (Rojas & Boxer, 2016). Ab is the major component of
extracellular plaques that accumulate throughout the brain of people
with AD (Querfurth & LaFerla, 2010). Ab is made from a larger
precursor, known as amyloid precursor protein (APP). APP is sequentially
cleaved by BACE1 and the c-secretase complex to generate Ab (Medina
et al., 2016). Full-length APP undergoes several post-translational
modifications, including phosphorylation at specific epitopes that
regulates its half-life and affinity for BACE1 (Lee et al., 2003; Ma et al.,
2012). This is particularly intriguing as reducing APP levels and/or
reducing its affinity of BACE1 could be valid approaches to lower Ab
levels.
The dual-specificity tyrosine phosphorylation-regulated kinase-1A
(Dyrk1a) is a protein kinase member of the Dyrk family, which includes
five kinases (Duchon & Herault, 2016). The DYRK1a gene is located in
the Down syndrome critical region on chromosome 21, which results in a
1.5-fold increase of Dyrk1a protein levels (Tejedor & Hammerle, 2011).
Dyrk1a levels are tightly regulated, as both overexpression and lack of
Dyrk1a activity are associated with mental retardation (Luco et al.,
2016). Dyrk1a can directly phosphorylate tau on numerous serine and
threonine residues (Ryoo et al., 2007; Azorsa et al., 2010). To this end,
overexpression of Dyrk1a contributes to the accumulation of NFT in
Down syndrome (Liu et al., 2008). In addition to its effects on tau
pathology, Dyrk1a appears to be linked to APP/Ab metabolism. For
example, in primary rat cortical neurons, Dyrk1a inhibition reduces tau
phosphorylation at multiple epitopes in a dose-dependent manner
(Coutadeur et al., 2015). The same inhibitor reduced Ab production in
HEK293 cells overexpressing APP (Coutadeur et al., 2015). This is
consistent with earlier findings showing that Dyrk1a phosphorylates APP
and enhances its affinity for BACE1 and the c-secretase complex,
thereby increasing overall Ab levels and plaque deposition (Wegiel et al.,
2011). Early evidence also suggests that Ab accumulation can facilitate
Dyrk1a activity (Kimura et al., 2007), creating a vicious cycle. Consistent
with these observations, Dyrk1a levels are increased in postmortem
human AD brains (Ferrer et al., 2005). Together, these data suggest that
reducing Dyrk1a activity could be a valid therapeutic strategy for
targeting both Ab and tau in AD (Adayev et al., 2011; Smith et al.,
2012). In this study, we test the effects of a new Dyrk1 inhibitor on the
AD-like phenotype of 3xTg-AD mice, a widely used animal model of AD
(Oddo et al., 2003).
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Results
Pharmacological characteristics of Dyrk-inh
The objective of this study was to assess whether Dyrk1 is a valid
therapeutic target for AD. To this end, we utilized a newly synthesized
Dyrk1 inhibitor (Dyrk1-inh). Dyrk1-inh is a benzimidazole-like com-
pound with a molecular weight in the 310-350 range (Fig. S1A; the
synthesis of Dyrk1-inh is shown in Patent number US2016/050198).
Dyrk1-inh is an ATP-competitive kinase inhibitor with excellent intrinsic
affinity and a clear dose-dependent inhibitory effect on Dyrk1a activity
(IC50: 34 nM; Fig. S2A). To probe for selectivity, we analyzed the
inhibitory effect of 10 lM Dyrk1-inh using the EZ reader electrophore-
sis mobility chip instrument (see Methods). The test was ran against
different kinases known to be involved in neurodegenerative pro-
cesses, such as GSK3b, CDK5, and CK1d. We found that at this
concentration, Dyrk1-inh inhibited >99% of Dyrk1a and Dyrk1b
activity (IC50: 124 and 129 nM, respectively; Fig. S2B). Dyrk1-inh also
had a modest effect on the activity of GSK3b and CDK5 (Fig. S2B). To
evaluate the permeability of Dyrk1-inh across the blood-brain barrier
(BBB), we utilized standard surrogate BBB assays such as the Parallel
Artificial Membrane Permeability Assay and Caco-2. We found that
Dyrk1-inh had a value of effective permeability (Pe) of 26.50
E-06 cm s1, which indicated that passive diffusion across the BBB
was likely. Using the Caco-2 permeability test, we found that Dyrk1-
inh had an efflux ratio of 0.5 (diffusion in an apical-
to-basolateral direction = 5.71; diffusion in a basolateral-to-apical
direction = 3.13) through a monolayer of Caco-2 cells. Taken
together, these results suggest that Dyrk1-inh crosses the BBB with
no significant efflux liabilities.
Dyrk1 inhibition improves learning and memory
To determine the effects of chronic inhibition of Dyrk1 on AD-like
pathology, we treated 10-month-old female 3xTg-AD (n = 13) and
NonTg (n = 15) mice with a Dyrk1 inhibitor (Dyrk1-inh), which was
delivered via daily intraperitoneal (i.p.) injections for eight weeks
(12.5 mg kg1). Herein, we refer to these mice as 3xTg-AD/DYR and
NonTg/DYR. Age- and gender-matched 3xTg-AD (n = 12) and NonTg
(n = 13) mice were injected with vehicle and used as control groups.
Herein, we refer to these mice as 3xTg-AD/veh and NonTg/veh
(Fig. S3A). During the dosing period, we weighed mice weekly and
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Fig. 1 Chronic Dyrk1 inhibition improves learning and memory in 3xTg-AD mice. (A, B) The graphs show total distance traveled and speed during the open-field test. The
data were not statistically significant among the four groups (P = 0.0957 and 0.1016, respectively). (C, D) The graphs show the time spent in the center and periphery of the
arena during open-field testing. The data were not statistically significant among the four groups (P = 0.7828 and 0.7827, respectively). (E-H) We then evaluated the
performance of the mice in the radial arm water maze (RAWM) by scoring spatial and working memory errors. The graphs show the average of the total errors that each
mouse made across the 15 trials/day. (E) All groups show a decrease in total spatial errors at day 2, indicating learning (time effect, P < 0.0001; group effect, P = 0.0002;
interaction effect, P = 0.1841). (F) When we analyzed the total number of spatial errors at day 2, we found significant differences between groups (P = 0.0001). As
indicated in the figure, post hoc analyses showed that 3xTg-AD/veh mice performed worse than all the other groups. Notably, 3xTg-AD/DYR mice performed better than
3xTg-AD/veh mice (P < 0.05) and as well as NonTg mice (P > 0.05). (G, H) Working memory errors: All the groups learned the task (time effect, P < 0.0001; group effect,
P = 0.0001 interaction effect, P = 0.4716). However, on day 2, we found significant differences between groups (P < 0.0001). Post hoc analyses indicated that 3xTg-AD/
DYR mice performed significantly better than 3xTg-AD/veh mice (P < 0.01) and as well as NonTg mice (P > 0.05). Both for working and reference errors, no differences were
detected between NonTg/veh and NonTg/DYR mice (P > 0.05). Data are presented as means  SEM. Data in panels A-D, F, and H were analyzed by one-way ANOVA
followed by Tukey’s post hoc analyses. Data in panels E and G were analyzed by two-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001.
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found that the body weight of mice in the 3xTg-AD/veh group was
significantly higher than all the other groups (Fig. S3B). At this age,
3xTg-AD mice are overweight, and the treatment with Dyrk1-inh
restored the normal body weight. Notably, no effect for the treatment
was elicited in NonTg mice (Fig. S3B).
During the last 3 weeks of i.p. injections, mice were tested in a
series of cognitive and noncognitive behavioral tests and were
sacrificed immediately after the completion of the behavioral tests
(Fig. S3A). We first used the open-field activity test to measure
general motor function. We found that spontaneous activity and gross
motor function were similar among the four groups (Fig. 1A–B), as
indicated by the total distance traveled and the average speed in the
activity chamber during the test. To evaluate general anxiety and
stress, we measured open-field thigmotaxis and the time spent in the
center of the activity chamber. We found that the time spent in the
periphery and the center was similar among the four groups (Fig. 1C–
D). Taken together, these data indicate that Dyrk1 inhibition has no
effects on body weight, general motor function, and anxiety-like
behavior, suggesting that under these experimental conditions, the
drug was well tolerated.
To assess the effect of the treatment on cognitive function, we
tested mice in the radial arm water maze. This task is routinely used
to measure reference and working memory, two memory domains
mainly dependent on the hippocampus and frontal cortex,
respectively (Hodges, 1996). During the first day of training, mice
received 15 consecutive trials to find a platform, which is alternated
between visible and hidden platform. Twenty-four hours after the
last training trial, mice received 15 additional trials, during which
the platform was always hidden. The total entries in arms without
the platform were considered reference memory errors, while the
number of reentries in an arm without the platform during the same
trial was considered as working memory errors. We found that the
overall reference memory errors between day 1 and day 2 were
significantly reduced for all four groups (Fig. 1E, P < 0.0001), which
suggests that all groups learned the task. In contrast, we found that
during day 2, there were significant differences among groups (one-
way ANOVA, P = 0.0001). Post hoc analyses with Tukey’s correction
showed that 3xTg-AD/veh mice made significantly more errors
compared to all the other groups (Fig. 1F). Notably, the treatment
mitigated these deficits; indeed, 3xTg-AD/DYR performed significantly
better than 3xTg-AD/veh and NonTg/veh mice (Fig. 1F). We found
similar results when we measured working memory errors. To this
end, 3xTg-AD/veh mice performed worse compared to all the other
groups. More importantly, 3xTg-AD/DYR mice performed significantly
better than 3xTg-AD/veh mice (P < 0.01) and as well as NonTg/veh
mice (Fig. 1G–H; P > 0.05). Taken together, these data indicate that
Dyrk1 inhibition significantly improves cognitive deficits in 3xTg-AD
mice.
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Fig. 2 Chronic Dyrk1 inhibition reduces tau pathology. (A) Western blot on brain lysates probed with the indicated antibodies (n = 4 mice/group for NonTg and n = 5 mice/
group for 3xTg-AD). (B) Quantitative analysis of the HT7 blot showed a genotype effect (P < 0.0001), as expected, but neither a treatment nor an interaction effect
(P = 0.5452 and 0.4102, respectively). (C) Quantitative analysis of the tau5 blot showed a genotype effect (P < 0.0001), but neither a treatment nor an interaction
effect (P = 0.9146 and 0.8895, respectively). (D) Quantitative analysis of the AT100 blot showed a genotype effect (P = 0.0117), but neither a treatment nor an interaction
effect (P = 0.4482 and 0.7140, respectively). (E) Quantitative analysis of the steady-state levels of ~50 kDa band of CP13 (black arrowhead) showed a genotype effect
(P < 0.0001), but neither a treatment nor an interaction effect (P = 0.2223 and 0.0662, respectively). (F–I) Western blot and quantitative analyses on insoluble brain fraction
probed for total and p-tau (S396). Quantitative analyses of the blots showed that total tau levels were similar between the two groups (P = 0.2890). In contrast, the steady-
state levels of ~50 kDa band (black arrowhead) normalized to protein concentration or to total tau levels were significantly decreased in the 3xTg-AD/DYR compared to 3xTg-
AD/veh (P = 0.005 and 0.0211, respectively). (L-M) Representative photomicrographs of treated and untreated 3xTg-AD brain slices probed with the CP13 antibody (n = 6
mice/group). Data in panels B-E were normalized to b-actin, presented as means  SEM, and analyzed by two-way ANOVA (genotype/treatment). Data in panels G-H were
normalized to protein concentration, presented as means  SEM, and analyzed by Student’s t-test. *P < 0.05.
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Dyrk1 inhibition decreases insoluble tau phosphorylation
To identify the neuropathological correlates of the improved cognitive
function in 3xTg-AD/DYR mice, at the end of the behavioral tests, we
analyzed their brains using biochemical and histological approaches.
Initially, we measured tau levels by Western blot. Specifically, we
analyzed human and endogenous soluble tau levels using the HT7 and
tau5 antibodies, respectively. Consistent with the presence of the tau
transgene, both 3xTg-AD groups had significantly higher HT7 levels
compared to both NonTg groups (P < 0.0001). However, Dyrk1-inh had
no effect on HT7 levels as we found no statistically significant difference
between 3xTg-AD/veh and 3xTg-AD/DYR mice (Fig. 2A–B). These data
suggest that Dyrk1-inh does not alter the expression of the transgene.
We found similar results when we measured endogenous mouse tau
levels: both 3xTg-AD groups had significantly higher tau5 levels than the
two NonTg groups (P < 0.0001), while the treatment did not alter total
tau levels (Fig. 2A,C). To further measure the effects on tau phospho-
rylation, we used CP13, an antibody raised against tau phosphorylated
at Ser202. We found that 3xTg-AD mice had higher CP13 levels than
NonTg mice (P < 0.0001), which were not affected by the treatment
(Fig. 2A,D). Given that hyperphosphorylated tau forms insoluble aggre-
gates, we measured the levels of insoluble total and phosphorylated tau
(S396). While the insoluble levels of total tau, as detected by the HT7
antibody, were similar between treated and untreated 3xTg-AD mice
(Fig. 2F–G), we found that Dyrk1-inh significantly reduced the levels of
insoluble tau phosphorylated at S396 in 3xTg-AD mice (Fig. 2F,H–I;
P = 0.005 and 0.021, respectively). Consistent with the Western blot
data, immunostaining of hippocampal sections from 3xTg-AD/veh and
3xTg-AD/DYR mice with the CP13 antibody showed similar immunore-
activity between the two groups (Fig. 2L–M). Together these data
indicate that Dyrk1-inh selectively reduces insoluble tau phosphorylation.
Further studies are needed to identify the mechanisms underlying this
selectivity.
Dyrk1 inhibition reduces Ab pathology
In addition to tau pathology, 3xTg-AD mice show age-dependent
accumulation of Ab pathology (Oddo et al., 2003, 2008). To
determine the effects of Dyrk1-inh on Ab load, we immunostained
hippocampal sections from 3xTg-AD/DYR and 3xTg-AD/veh mice with
an Ab42 specific antibody. We found that Ab immunoreactivity was
markedly reduced in 3xTg-AD/DYR mice compared to 3xTg-AD/veh
mice (Fig. 3A–B). Quantitative analysis of the plaque load showed that
this difference was statistically significant (Fig. 3C; P = 0.0218). To
further assess the effects of Dyrk1-inh on Ab pathology, we measured
Ab levels by sandwich ELISA. Surprisingly, we found that soluble Ab40
and Ab42 levels were not statistically different between 3xTg-AD/DYR
and 3xTg-AD/veh mice (Fig. 3D). In contrast, insoluble Ab40 and
Ab42 levels were significantly lower in 3xTg-AD/DYR mice compared
to 3xTg-AD/veh mice (Fig. 3E, P = 0.0215 and 0.0239, respectively),
which is consistent with the effects on Ab load measured by
immunohistochemistry.
Fig. 3 Dyrk1 inhibition reduces amyloid-b (Ab) pathology. (A-B) Representative photomicrographs of 3xTg-AD mice treated with Dyrk1-inh or vehicle
(n = 6 mice/group). Sections were immunostained with an Ab42-specific antibody from Millipore. (C) The graph shows a significant decrease in the average area occupied in
the hippocampus by plaques in treated vs. untreated 3xTg-AD mice (P = 0.0218). (D) Enzyme-linked immunosorbent assay measurements from brain lysates (n = 11 mice/
group) revealed no difference in both Ab40 and Ab42 levels in the soluble fraction (P = 0.6010 and P = 0.8539, respectively). (E) In contrast, insoluble Ab40 and Ab42
levels were significantly reduced in the brains of 3xTg-AD/DYR mice compared to 3xTg-AD/veh (P = 0.0215 and P = 0.0239, respectively). Data are presented as
means  SEM and were analyzed by Student’s t-test. *P < 0.05.
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To begin understanding the mechanisms underlying the reduction in
Ab, we first focused on APP processing. We found that the 3xTg-AD
groups had higher full-length APP levels compared to both NonTg
groups (genotype effect, P < 0.0001; Fig. 4A–B). Post hoc analyses
indicated that APP levels were significantly lower in 3xTg-AD/DYR mice
compared to 3xTg-AD/veh mice (P < 0.01). Consistent with the APP
levels, C83 and C99 levels were also subjected to a genotype effect
(P < 0.0001). Specifically post hoc analyses revealed that C99 and C83
levels in 3xTg-AD/DYR mice were significantly lower than 3xTg-AD/veh
mice (P < 0.01; Fig. 4A,C–D). Taken together, these data indicate that
the reduction in Ab levels might be mediated by changes in APP levels
and processing. To understand the mechanisms linking Dyrk1 inhibition
to APP processing and Ab production, we measured APP levels
phosphorylated at Thr668 (APP/Thr668), which regulates APP turnover
and processing (Lee et al., 2003; Ma et al., 2012). To this end,
phosphorylation at Thr668 increases APP stability (Ma et al., 2012),
enhancing BACE1 cleavage of APP. Further, APP/Thr668 levels are
increased in AD human brains (Lee et al., 2003). We focused on APP/
Thr668 as Dyrk1a is one of the known protein kinases responsible for
phosphorylation of APP at this specific epitope (Ryoo et al., 2008). While
the ratio of APP/Thr668 over total APP was not statistically significant
between the two groups, we found that Dyrk1-inh significantly reduces
the overall steady-state levels of APP/Thr668 levels (Fig. 5A–C;
P = 0.048). To determine how the Dyrk1-inh-mediated changes in APP
phosphorylation impact APP catabolism, we measured the amount of
APP localized in the lysosomes by confocal microscopy. We found that
the amount of colocalization between APP and the lysosomes was
significantly increased in 3xTg-AD/DYR mice compared to 3xTg-AD/veh
mice (Fig. 5C–E; P = 0.0436). To confirm a direct effect of Dyrk1 on APP
levels and catabolism, we performed an in vitro experiment using the
HT22 cell line. We treated cells for 24 h with increasing concentrations
of Dyrk1-inh or vehicle and found a decrease in APP levels in a dose-
dependent manner (Fig. 6A). To dissect the mechanisms of this
reduction, using the same experimental condition, we inhibited the
lysosome function (by adding ammonium chloride) and measured the
levels of APP. Notably, inhibiting lysosomal function prevented the
reduction in APP levels elicited by the Dyrk1-inh (Fig. 6B). Overall, our
data suggest that Dyrk1-inh increased APP turnover, thus reducing Ab
production.
Discussion
There are no current means to slow the progression of AD effectively. In
this proof-of-concept study, we report that Dyrk1 is a valid new target
for AD treatment and show that its chronic inhibition reduced Ab and
tau pathology and ameliorated cognitive deficits in 3xTg-AD mice. These
data are consistent with previous results indicating that CX-4945, a
selective and potent Dyrk1a inhibitor, reduces tau pathology in multiple
systems (Kim et al., 2016). Taken together these results clearly indicate
that Dyrk1 represents a valid therapeutic target for AD and support the
development of new, effective, and clinically safe compounds aimed at
reducing Dyrk1 activity.
In postmortem human AD patients, Dyrk1a activity is increased in
several brain regions and is enriched in fractions containing phospho-
rylated tau, suggesting a possible contribution of this kinase in tau
pathogenesis (Ferrer et al., 2005). The gene encoding Dyrk1a is located
on chromosome 21, within the Down syndrome (DS) critical region
(Ronan et al., 2009). Virtually 100% of people with DS will show brain
accumulation of Ab and tau in their fifth decade of life, and the vast
majority of them will develop dementia by the age of 60 (Coppus et al.,
2006; Head et al., 2012, 2016). To this end, several groups have
suggested that Dyrk1a may represent a functional link between DS and
AD (Kimura et al., 2007; Ryoo et al., 2007, 2008). For example, Dyrk1a
phosphorylates tau at Thr212 in vitro (Woods et al., 2001), a residue
that is hyperphosphorylated in AD. This is remarkable, as phosphoryla-
tion at this epitope primes tau for phosphorylation by GSK3b at other
AD-related epitopes (Woods et al., 2001). In mouse models, more
contradictory results have been found. In DS mice, which are charac-
terized by increased Dyrk1a activity, the levels of tau phosphorylated at
several epitopes were increased (Liu et al., 2008). In contrast, transgenic
mice overexpressing Dyrk1a do not show changes in tau phosphoryla-
tion at Thr212 (Ferrer et al., 2005). Together, these data suggest that
the link between Dyrk1a and tau is complex. Our results indicate that
Dyrk1 inhibition reduces tau phosphorylation only in the insoluble
fraction; these findings are consistent with the observation that in
human AD brains Dyrk1a is associated with tau in the sarkosyl-insoluble
fraction (Ferrer et al., 2005).
Dyrk1a has also been involved in APP processing and Ab generation
(Wegiel et al., 2011). Early work indicated that Dyrk1a, along with other
kinases, directly phosphorylates APP at Thr668 in vitro (Park et al., 2007;
Ryoo et al., 2008). Consistently, Dyrk1 transgenic mice show high levels
of phosphorylated APP and increased Ab levels (Ryoo et al., 2008).
Furthermore, by phosphorylating APP and enhancing the amyloidogenic
processing of APP, Dyrk1a increases Ab production (Lee et al., 2003;
Vingtdeux et al., 2005; Park et al., 2007). In postmortem human AD
Fig. 4 Dyrk1 inhibition alters APP processing. (A) Representative Western blots of
proteins extracted from the brains of treated and untreated NonTg (n = 4 mice/
group) and 3xTg-AD (n = 5 mice/group) mice. Blots were probed with the
indicated antibodies. (B) Quantitative analysis of the full-length APP blot showed a
genotype effect (P < 0.0001), and a genotype-treatment interaction effect
(P = 0.0074). Moreover, Bonferroni’s post hoc analysis showed a significant
reduction of full-length APP for 3xTg-AD/DYR (P < 0.01). (C–D) Quantitative
analysis of the C83 and C99 blots showed a genotype effect (P < 0.0001).
Moreover, C99 and C83 levels were significantly decreased by treatment
(P < 0.01). Data were normalized to b-actin, presented as means  SEM, and
analyzed by two-way ANOVA (genotype/treatment) followed by post hoc
Bonferroni’s comparison. *P < 0.05.
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brains, the levels of APP phosphorylated at Thr668 are increased (Lee
et al., 2003). Consistent with these observations, here we report that
Dyrk1-inh significantly decreases the steady-state levels of APP phos-
phorylated at Thr668, which in turn leads to lower C99 levels and Ab
deposition.
In summary, we report that chronic Dyrk1 inhibition synergistically
reduces Ab and tau pathology. This is noteworthy as there is growing
appreciation that combination therapies might be needed to successfully
mitigate AD progression (Gao et al., 2016). Therefore, the identification
of targets, that could affect different pathological markers, represents a
step forward in developing new therapeutics for AD.
Experimental procedures
Mice
The 3xTg-AD mice were generated as previously described (Oddo et al.,
2003). In our colony of 3xTg-AD mice, the AD-like pathology in males is
extremely variable. In contrast, the onset and progression of the
phenotype in female 3xTg-AD mice are very predictable, and the
variability from animal to animal is minimal. Thus, only female mice were
used. All mice were housed 4–5 per cage, kept on 12-h light/dark cycle
and were given ad libitum access to food and water. Animal care and
treatments were in accordance with the applicable regulations in the
vivarium (The Institutional Animal Care and Use Committee of the
Banner Sun Health Research Institute).
Dyrk1-inh
Dyrk1-inh was synthesized by Dr. Hulme at the University of Arizona. It is
an ATP-competitive kinase inhibitor with excellent intrinsic affinity and a
clear dose-dependent inhibitory effect on Dyrk1a activity (IC50: 34 nM;
Fig. S1A). For the chronic treatment, Dyrk1-inh was delivered via daily
intraperitoneal (i.p.) injections for eight weeks, at 12.5 mg kg1 in 50%
PEG-400 and 50% 0.9% NaCl. Control mice were injected with an equal
volume of vehicle. Mouse weights were monitored throughout the
dosing period.
In vitro experiments
The Z’-LYTETM Detection Kinase Assay Kit (ThermoFisher Scientific,
Waltham, MA, USA) was used to generate the inhibition curve. The
Dyrk1a-specific substrate peptide was labeled with a FRET pair (2
fluorophores, one at each end of the peptide). The reaction was
conducted in the presence of recombinant Dyrk1a and 10 lM ATP.
When a Dyrk1a inhibitor is present, the peptide is not phosphorylated,
so it is more sensitive to cleavage. The peptide cleavage disrupts the
FRET emission. By analyzing the emission ratio, it is possible to quantify
the reaction progress. To evaluate selectivity, we then used the EZ
Reader Electrophoresis Mobility Chip Instrument (Caliper Life Science,
Hopkinton, MA, USA). This system allows the user to follow the reaction
by analyzing the shift in electrophoretic mobility between the nonphos-
phorylated and phosphorylated peptides. The experiment was con-
ducted according to the manufacturer’s instructions in the presence of
45 lM ATP. The Parallel Artificial Membrane Permeability Assay
(PAMPA) was performed using the BD GentestTM precoated PAMPA
plate system (Analiza Inc, OH, USA), following the manufacturer’s
instructions. Caco-2 cells (clone C2BBe1) were obtained from American
Type Culture Collection (Manassas, VA, USA). Cell monolayers were
grown to confluence on polycarbonate membranes in Costar Transwell
plates. Cell monolayers were incubated at 37°C with 5% CO2 in a
humidified incubator. Samples (in duplicate) were taken from the donor
Fig. 5 Dyrk1 inhibition reduces APP phosphorylation, thereby modifying APP turnover. (A) Representative Western blots of proteins extracted from the hippocampi of
treated and untreated 3xTg-AD mice (n = 9 mice/group). Blots were probed with the indicated antibodies. (B-C) Quantitative analysis of the blots showed that while Dyrk1
inhibition did not change the ratio of phosphorylated over total APP, it significantly reduced the overall steady-state levels of phosphorylation of APP at Thr668 (P = 0.0480).
However, the ratio pAPP over total APP was not significantly different between the two groups. (D–E) Representative microphotographs of hippocampal sections
immunostained with the indicated antibodies (n = 30 pictures from 6 mice/group). (F) Semiquantitative analysis showed that the number of yellow pixels (indicating a
colocalization between APP and the lysosomal protein Lamp2A, analyzed as Pearson’s correlation coefficient) was significantly higher in 3xTg-AD/DYR mice compared with
3xTg-AD/veh mice (P = 0.0436). Data are presented as means  SEM and were analyzed by Student’s t-test. *P < 0.05.
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and receiver chambers at 120 min and were assayed by LC-MS/MS
using electrospray ionization. Further analysis of each monolayer was
performed to ensure the integrity of the cell monolayers at the end of
the experiment. The in vitro kinase assay used to evaluate Dyrk1-inh
capability of reducing tau phosphorylation at S396 was conducted as
previously reported (Frost et al., 2011).
Behavioral analyses
The open field is a commonly used qualitative and quantitative measure
of general locomotor activity and willingness to explore in rodents. It was
performed as previously described (Caccamo et al., 2012). Radial arm
water maze. The radial arm water maze (RAWM) task is utilized to assess
hippocampal-dependent spatial reference and working memory, and it
was performed as previously described (Medina et al., 2014). A video
camera recorded each mouse. The experimenter, who was blind to the
genotype and treatment, scored the entries into arms. The dependent
measures were incorrect arm entries (reference memory errors) and
reentries (working memory errors).
Protein extraction
Mice were killed by CO2 asphyxiation and their brains were removed and
sagittally bisected. Half of the brain was fixed in 4% paraformaldehyde
and used for immunohistochemical experiments. The other half was
collected and stored at 80°C until use. Frozen brains (without
cerebellum) were processed as described previously (Caccamo et al.,
2013). Briefly, brains were homogenized in a solution of tissue protein
extraction reagent (T-PER; ThermoFisher Scientific) containing
0.7 mg mL1 of pepstatin A supplemented with a complete mini
protease inhibitor tablet (Roche Applied Science, Indianapolis, IN, USA)
and phosphatase inhibitors (Millipore, Billerica, MA, USA). The homog-
enized mixtures were centrifuged at 4°C for 1 h at 100 000 g, and the
resulting supernatant was stored as the soluble fraction. The pellet was
then homogenized in 70% formic acid and centrifuged as described
above. The supernatant was stored as the insoluble fraction.
Western blot and ELISA
Proteins from insoluble and soluble fractions were resolved by 10% Bis-
Tris SDS-polyacrylamide gel electrophoresis (ThermoFisher Scientific)
under reducing conditions and transferred to a nitrocellulose membrane.
Membranes were developed as described previously (Orr et al., 2014).
Ab40 and Ab42 levels were determined with commercial ELISA kits
(ThermoFisher Scientific), and experiments were conducted using the
manufacturer’s instructions.
Immunohistochemistry and immunofluorescence
Brains were processed as previously described (Branca et al., 2014).
Briefly, hemibrains were drop fixed in 4% paraformaldehyde in
phosphate-buffered saline for 48 h and then transferred into 0.02%
sodium azide in phosphate-buffered saline until slicing; 50-lm-thick
free-floating sections were subsequently obtained using a vibratome. For
immunohistochemistry, sections were washed twice with TBS (100 mM
Tris pH 7.4, 150 mM NaCl) and incubated for 30 min in 3% H2O2, to
quench endogenous peroxidase activity. Next, sections were transferred
into TBS-A (100 mM Tris pH 7.4, 150 mM NaCl, 0.1% Triton X-100) and
TBS-B (100 mM Tris pH 7.4, 150 mM NaCl, 0.1% Triton X-100, 2%
bovine serum albumin) for 15 and 30 min, respectively. Finally, the
proper primary antibody was applied overnight at 4°C. Sections were
washed to remove excess antibody and incubated in the suitable
secondary antibody for 1 h at room temperature. Signal was enhanced
by incubating sections in the avidin–biotin complex (Vector Labs) for 1 h.
Sections were then washed and developed with diaminobenzidine
substrate using the avidin–biotin horseradish peroxidase system (Vector
Labs, Burlingame, CA, USA). Images were obtained with a digital Zeiss
camera and analyzed using ImageJ. For immunofluorescence staining,
the same protocol was followed with small differences. The step of
quenching was skipped, and after the secondary antibody (AlexaFluor;
ThermoFisher Scientific), the slices were mounted and coverslip with
Prolong diamond mounting (ThermoFisher Scientific). Images were
obtained with a Leica Confocal microscope and analyzed using ImageJ.
For all colocalization measurements, lasers 561 nm and 488 nm were
used for excitation of secondary antibody fluorophores Alexa555 and
Alexa488, respectively. To obtain a Pearson correlation coefficient (PCC),
ImageJ plugin ‘Coloc2’ was used. To quantify Ab pathology, images
from six mice/group were taken with a Zeiss AxioImager A1 using a 59
objective. Images were then merged to rebuild the whole slice. Merged
images were analyzed using ImageJ, and the percentage of area
occupied by plaques was graphed.
Cell culture
HT22 cells were seeded at a density of 1.25 9 105 cells cm2 in
21 cm2 culture dishes (ThermoFisher Scientific) in DMEM culture
Fig. 6 Dyrk1 inhibition reduces APP levels by a lysosomal-dependent mechanism.
(A) Immunoblot analysis (anti-APP antibody clone 22C11) of total extracts from
HT22 cells treated for 24 hours with different concentrations of Dyrk1-inh. One-
way ANOVA analysis showed a significant effect (P = 0.0011). Post hoc analyses
with Tukey’s correction showed that the reduction in APP levels was significantly
different starting at 7.5 lM Dyrk1-inh. (B) Immunoblot analysis (anti-APP antibody
clone 22C11) of total extracts from HT22 cells treated for 24 h with 7.5 lM Dyrk1-
inh in the presence or absence of the lysosomal inhibitor ammonium chloride
(2 mM). One-way ANOVA analysis showed a significant effect (P = 0.0069). Post
hoc analyses with Tukey’s correction showed that the reduction in APP levels
elicited by Dyrk1-inh treatment is reversed by lysosomal inhibition. Data were
generated by normalizing the levels of the protein of interest to b-actin used as
loading control. Results presented as means  SEM of three independent
experiments. *P < 0.05.
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medium (ThermoFisher Scientific) containing 10% fetal bovine serum.
Cells were grown to confluence in a 5% CO2 and 95% air humidified
atmosphere. Cells were then incubated in DMEM without serum and
exposed for 24 h to different concentrations of the Dyrk1 inhibitor
(2.5–12.5 lM) dissolved in dimethyl sulfoxide (DMSO; 0.1% final
concentration), or to the DMSO vehicle alone. To inhibit lysosomal
activity, ammonium chloride was added at the same time of the Dyrk1
inhibitor (2 mM). Proteins were extracted in RIPA buffer and used for
immunoblot assay.
Antibodies
From Cell Signaling Technology (Danvers, MA, USA): phospho-APP
(T668) (Cat. #3823, 1:1000) and b-actin (Cat. #3700, 1:10,000). From
Millipore, Ab42 (Cat. #AB5078P, 1:200), and Anti-APP A4, clone 22C11
(Cat. #MAB348, 1:1000). From Covance (Princeton, NJ, USA), APP (Ab
amino acids 1–16) monoclonal antibody, 6E10 (Cat. #MAB1560,
1:3,000). From Abcam (Cambridge, MA, USA), Lamp2a (Cat.
#ab18528,1:200) and phospho-tau (S396) (Cat. #ab109390, 1:1000).
From Sigma-Aldrich (St. Louis, MO, USA), amyloid precursor protein
(APP) C-terminal (Cat. #A8717, 1:1,000). From ThermoFisher Scientific,
HT7 (Cat. #MN1000, 1:5,000) and tau5 (Cat. #577801, 1:2,000). CP13
(1:1000) was a generous gift from Dr. Peter Davies.
Statistical analyses
All data were analyzed using GraphPad Prism (GraphPad Software,
CA, USA, www.graphpad.com). Data were analyzed by one- or
two-way ANOVA followed by Bonferroni’s post hoc analysis or
Tukey’s multiple comparison tests, when applicable. Selective
experiments were analyzed by Student’s t-test, as specified in the
figure legends.
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